Pharmacokinetic aspects of naloxone-precipitated morphine withdrawal in male and female prepubertal mice

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 6, 2007, Pages 283-289

  Diaz, Silvina L ^a   Hermida, María P ^a,b   Joannas, Leonel D ^a   Olivera, Mónica ^b   Ridolfi, Adriana ^b   Villaamil, Edda C ^b   Balerio, Graciela N ^a,b  

^a Instituto de Investigaciones Farmacologicas   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Morphine; Naloxone; Plasma levels; Prepubertal mice; Sex

Indexed keywords

MORPHINE; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MORPHINE ADDICTION; MOUSE; NONHUMAN; PREPUBERTY; SEX DIFFERENCE; TIME; TOXICOKINETICS; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALF-LIFE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NARCOTIC ANTAGONISTS; SEX FACTORS; SEXUAL MATURATION; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 34548744697     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.554     Document Type: Article

References (41)

1. Caggiula AR, Donny EC, White AR, et al. Environmental stimuli promote the acquisition of nicotine self-administration in rats. Psychopharmacology (Berl) 2002; 163: 230-237. DOI: 10.1007/ s00213-002-1156-5
2. Lynch WJ, Roth ME, Carroll ME. Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmcology (Berl) 2002; 164: 121-137. DOI: 10.1007/s00213-002-1183-2
3. Carroll ME, Lynch WJ, Roth ME, Morgan AD, Cosgrove KP. Sex and estrogen influence drug abuse. Trends Pharmacol Sci 2004; 25: 273-279. DOI: 10.1016/j.tips.2004.03.011
4. Baamonde AI, Hidalgo A, Andrés-Trelles F. Sex-related differences in the effects of morphine and stress on visceral pain. Neuropharmacology 1989; 28: 967-970. DOI: 10.1016/ 0028-3908(89)90197-4
5. Kepler KL, Standifer KM, Paul D, Kest B, Pasternak GW, Bodnar RJ. Gender effects and central opioid analgesia. Pain 1991; 45: 87-94. DOI: 10.1016/0304-3959(91)90168-W
6. Islam AK, Cooper ML, Bodnar RJ. Interactions among aging, gender, and gonadectomy effects upon morphine antinociception in rats. Physiol Behav 1993; 54: 45-53. DOI: 10.1016/0031-9384(93)90042-E
7. Cicero TJ, Nock B, Meyer ER. Gender-related differences in the antinociceptive properties of morphine. J Pharmacol Exp Ther 1996; 279: 767-773.
8. Craft RM. Sex differences in opioid analgesia: 'From mouse to man'. Clin J Pain 2003; 19: 175-186.
9. Candido J, Lutfy K, Billings B, et al. Effect of adrenal and sex hormones on opioid analgesia and opioid receptor regulation. Pharmacol Biochem Behav 1992; 42: 685-692. DOI: 10.1016/ 0091-3057(92)90015-8
10. Craft RM, Stratmann JA, Bartok RE, Walpole TI, King SJ. Sex differences in development of morphine tolerance and dependence in rat. Psychopharmacology (Berl) 1999; 143: 1-7. DOI: 10.1007/ s002130050911
11. Kest B, Adler M, Hopkins E. Sex differences in thermo-regulation after acute and chronic morphine administration in mice. Neurosci Lett 2000; 291: 126-128. DOI: 10-1016/S0304-3940(00)01393-8
12. Stewart J, Rodaros D. The effects of gonadal hormones on the development and expression of the stimulant effects of morphine in male and female rats. Behav Brain Res 1999; 102: 89-98. DOI: 10.1016/ S0166-4328(99)00002-9
13. Cicero TJ, Ennis T, Ogden J, Meyer ER. Gender differences in the reinforcing properties of morphine. Pharmacol Biochem Behav 2000; 65: 91-96. DOI: 10.1016/S0091-3057(99)00174-4
14. Cicero TJ, Aylward SC, Meyer ER. Gender differences in the intravenous self-administration of μ opiate agonists. Pharmacol Biochem Behav 2003; 74: 541-549. DOI: 10.1016/S0091-3057(02)01039-0
15. Bodnar RJ, Hadjimarkou MM, Krzanowska EK, Silva RM, Stein JA. Differential dose-dependent effects of central morphine treatment upon food intake in male and female rats receiving neonatal hormone manipulations. Nutr Neurosci 2003; 6: 53-57. DOI: 10.1080/ 1028415021000042848
16. Diaz SL, Kemmling AK, Rubio MC, Balerio GN. Lack of sex-differences in the prevention by baclofen of the morphine withdrawal syndrome in mice. Behav Pharmacol 2001; 12: 75-79.
17. Diaz SL, Kemmling AK, Rubio MC, Balerio GN. Morphine withdrawal syndrome: involvement of the dopaminergic system in prepubertal male and female mice. Pharmacol Biochem Behav 2005; 82: 601-607. DOI: 10.1016/j.pbb.2005.10.012
18. Diaz SL, Kemmling AK, Bonavita CD, Rubio MC, Balerio GN. Baclofen reestablishes the μ-opioid receptor levels modified by the morphine withdrawal syndrome in either sexes. Synapse 2004; 54: 24-29, DOI: 10.1002/syn.20061
19. Diaz SL, Barros VG, Antonelli MC, Rubio MC, Balerio GN. Morphine withdrawal syndrome and its prevention with baclofen: autoradiographic study of μ-opioid receptors in prepubertal male and female mice. Synapse 2006; 60: 132-140. DOI: 10.1002/syn.20279
20. Baker L, Ratka A. Sex-specific differences in levels of morphine, morphine-3-glucuronide, and morphine antinociception in rats. Pain 2002; 95: 65-74. DOI: 10.1016/S0304-3959(01)00376-1
21. Cicero TJ, Nock B, Meyer ER. Sex-related differences in morphine's antinociceptive activity: relationship to serum and brain morphine concentration. J Pharmacol Exp Ther 1997; 282: 939-944.
22. SENASA. Resolución 617/2002: Requisitos, condiciones y procedimientos para la habilitación técnica de laboratorios que posean bioterios de producción, mantenimiento y local de experimentación.
23. Varian Sample Preparations Products. Extraction of Drugs of Abuse using Bond Elut Certify. Certify Methods Manual, 55-56.
24. Franklin M, Odontiadis J. Determination of naloxone in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr B 1996; 679: 199-203. DOI: 10.1016/ 0378-4347(95)99571-4
25. Zarrindast M, Mousa-Ahmadi E. Effects of GABAergic system on naloxone-induced jumping in morphine-dependent mice. Eur J Pharmacol 1999; 381: 129-133. DOI: 10.1016/ S0014-2999(99)00546-4
26. Achilli G, Cellerino GP, Melzi d'Eril GV, Tagliaro F. Determination of illicit drugs and related substances by high-performance liquid chromatography with an electrochemical coulometric-array detector. J Chromatogr A 1996; 729: 273-277. DOI: 10.1016/ 0021-9673(95)01095-5
27. Projean D, Minh Tu T, Ducharme J. Rapid and simple method to determine morphine and its metabolites in rat plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 787: 243-253. DOI: 10.1016/S1570-0232(02)00726-2
28. Gardmark M, Ekblom M, Bouw R, Hammarlund-Udenaes M. Quantification of effect delay and acute tolerance development to morphine in the rat. J Pharmacol Exp Ther 1993; 267: 1061-1067.
29. Ouellet DM, Pollack GM. Pharmacodynamics and tolerance development during multiple intravenous bolus morphine administration in rats. J Pharmacol Exp Ther 1997; 281: 713-720.
30. Alavi FK, Alavi K, McCann JP, Sangiah S, Clarke CR. Effect of dietary obesity on naloxone disposition in sheep. Can J Physiol Pharmacol 1994; 72: 471-475.
31. Berkowitz BA, Ngai SH, Hempstead J, Spector S. Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther 1975; 195: 499-504.
32. Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet 1976; 1: 219-230.
33. Armijo JA. Absorción, distribución y eliminación de los fármacos. In Fartnacología humana, Flórez J, Armijo JA, Mediavilla A (eds). Masson: Barcelona, 1997; 47-49.
34. Lötsch J. Pharmacokinetic-pharmacodynamic modelling of opioids. J Pain Symptom Manage 2005; 29: 90-103. DOI:10.1016/ j.jpainsymman.2005.01.012
35. Ferrero A. Proteínas. In Fundamentos de Química Biológica para Carreras Biomédicas, Vera G, Ferrero A (eds). Mar de Fondo: Buenos Aires, 2005; 105.
36. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci 1989; 86: 695-698.
37. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698-1705.
38. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC. The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical micro-dialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol 1999, 128: 563-568. DOI: 10.1038/ sj.bjp.0702804
39. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474-489. DOI: 10.1067/mcp.2002.128388
40. Frohlich M, Albermann N, Sauer A, Walter-Sack I, Haefeli WE, Weiss J. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 2004; 68: 2409-2416. DOI: 10.1016/j.bcp.2004.08.026
41. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995; 275: 1011-1018.